Someone who know's what he's talking about:

This ASX biotech stock could be the next M&A target

The headline refers to IMM but also references CYP.

Andrew Hamilton is a portfolio manager at Antares Equities. The Melbourne-based firm oversees about $5.7 billion.

What’s a stock you like that (most) investors wouldn’t have heard of?

The potential of adult stem cells has been known for two decades but turning science into therapies has proven very difficult, partly because of the challenges of producing enough cells of sufficient quality and consistency to be commercially viable and acceptable to regulators. Cynata have developed a process that overcomes these manufacturing challenges and, they hope, will allow them to develop successful therapies. I’m hoping because they are still in relatively early-stage clinical trials, but so far, the data is promising, and they’ve had a number of papers published in high-quality peer-reviewed publications.

https://www.copyright link/markets/equity-markets/this-asx-biotech-stock-could-be-the-next-m-and-a-target-20241205-p5kw06